In the PIONEER AF-PCI trial [5], the rates of clinically significant bleeding associated with once-daily rivaroxaban 15 mg (75% of the usual dose) and a P2Y12 inhibitor (dual therapy) as well as the rates associated with very low-dose rivaroxaban (2.5 mg twice daily) plus DAPT (triple therapy) were lower than rates experienced with triple therapy with warfarin plus DAPT. The gene discussed is P2RY12; the disease is atrial fibrillation.